Characterization of the GHB Withdrawal Syndrome.
GHB
abstinence
addiction
dependence
detoxification
gamma-hydroxybutyric acid
sex differences
treatment
withdrawal
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
08
04
2021
revised:
23
05
2021
accepted:
25
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
The gamma-hydroxybutyric acid (GHB) withdrawal syndrome can have a fulminant course, complicated by severe complications such as delirium or seizures. Detoxification by tapering with pharmaceutical GHB is a safe way to manage GHB withdrawal. However, a detailed description of the course of the GHB withdrawal syndrome is currently lacking. This study aimed to (1) describe the course of GHB withdrawal symptoms over time, (2) assess the association between vital signs and withdrawal symptoms, and (3) explore sex differences in GHB withdrawal. In this observational multicenter study, patients with GHB use disorder (
Identifiants
pubmed: 34073640
pii: jcm10112333
doi: 10.3390/jcm10112333
pmc: PMC8199158
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerie van Volksgezondheid, Welzijn en Sport
ID : 316997
Références
Neuropharmacology. 2000 Jan 28;39(3):427-39
pubmed: 10698009
Exp Clin Psychopharmacol. 2007 Feb;15(1):21-36
pubmed: 17295582
Drug Alcohol Depend. 2004 Jul 15;75(1):3-9
pubmed: 15225884
N Engl J Med. 2014 Nov 27;371(22):2109-13
pubmed: 25427113
Exp Clin Psychopharmacol. 2015 Dec;23(6):415-21
pubmed: 26461168
Clin Psychol Rev. 2018 Dec;66:12-23
pubmed: 29174306
Br J Clin Pharmacol. 2016 May;81(5):980-8
pubmed: 26659543
J Formos Med Assoc. 2018 Dec;117(12):1124-1127
pubmed: 29933901
Br J Addict. 1989 Nov;84(11):1353-7
pubmed: 2597811
Can J Psychiatry. 2003 Feb;48(1):5-13
pubmed: 12635558
Am J Drug Alcohol Abuse. 1987;13(3):293-308
pubmed: 3687892
Psychiatry Res. 2012 Aug 15;198(3):457-62
pubmed: 22424905
Crit Care Explor. 2020 Apr 29;2(4):e0089
pubmed: 32426731
Neuropsychobiology. 2016;73(2):65-80
pubmed: 27003176
CNS Drugs. 2014 May;28(5):401-10
pubmed: 24781751
J Addict Med. 2016 Jul-Aug;10(4):229-35
pubmed: 27310146
Drug Alcohol Depend. 2017 Jan 01;170:164-173
pubmed: 27923198
Addiction. 2009 Feb;104(2):256-65
pubmed: 19149822
Addiction. 2020 Mar;115(3):473-479
pubmed: 31618793
Eur J Pharmacol. 2001 Oct 12;428(3):315-21
pubmed: 11689189
Eur Addict Res. 2007;13(2):81-8
pubmed: 17356279
J Addict Med. 2019 Sep/Oct;13(5):415-417
pubmed: 30907765
Drug Alcohol Depend. 2017 Nov 1;180:260-264
pubmed: 28938183
Curr Opin Psychiatry. 2005 May;18(3):249-55
pubmed: 16639148
CNS Drugs. 2020 Jun;34(6):651-659
pubmed: 32319006
CNS Drugs. 2018 May;32(5):437-442
pubmed: 29651711
Ind Psychiatry J. 2013 Jul;22(2):100-8
pubmed: 25013309
Addiction. 2010 May;105(5):862-71
pubmed: 20331557
J Med Toxicol. 2006 Jun;2(2):55-60
pubmed: 18072114
Alcohol. 2014 Jun;48(4):375-90
pubmed: 24657098
CNS Drugs. 2017 Jan;31(1):51-64
pubmed: 28004314
Australas Psychiatry. 2019 Jun;27(3):284-287
pubmed: 30652947
Ann Emerg Med. 2001 Dec;38(6):660-5
pubmed: 11719746
Drugs. 2015 Mar;75(4):353-65
pubmed: 25666543
Am J Addict. 2015 Oct;24(7):590-8
pubmed: 26346395
Arch Gen Psychiatry. 2009 Jul;66(7):785-95
pubmed: 19581570
J Pharmacol Exp Ther. 1999 Jul;290(1):303-9
pubmed: 10381791
Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23
pubmed: 21854273
Curr Neuropharmacol. 2015 Jan;13(1):47-70
pubmed: 26074743
Eur Addict Res. 2012;18(1):40-5
pubmed: 22142784
Alcohol Alcohol. 2014 May-Jun;49(3):287-91
pubmed: 24407777
Clin Toxicol (Phila). 2015 Nov;53(9):893-900
pubmed: 26503789